The Department of Health and Human Services said on Friday it would refer the company to the Department of Justice but did not make clear whether it could quickly halt the sale of the Hims' product, the cheapest GLP-1 therapy on the U.S

In fact, cardiovascular disease represents the leading cause of death for patients with NAFLD.[15], [16] When focussing on liver-related morbidity and mortality, NASH represents the third most common cause of cirrhosis within the United States, but it is predicted to become the leading cause over the next few years.17 NASH cirrhosis is currently the primary aetiology for dual liver-kidney transplantation and is estimated to become the number one indication for liver transplant by 2020.[18], [19], [20] Overall, the distinction between those with NAFLD and those with NASH is clinically relevant given that multiple studies have demonstrated that patients with NASH are at higher risk of adverse liver-related outcomes, with the degree of fibrosis contributing most significantly to this increased risk.[3], [21], [22] The striking prevalence of NAFLD paired with its profound complications underscores the critical need for safe, effective, and broadly applicable therapy

Traditional post-discharge care methods may fail to capture the full scope of patient recovery, highlighting the need for improved monitoring strategies
What Are the Main Differences Between GLP-1 Weight Loss Injections Like Wegovy, Ozempic, and Saxenda